

POLY MEDICURE B.V.

Amsterdam, The Netherlands

Annual Report

(For the year ended 31st March 2021)

Address of the Company : Keizersgracht 391 A, 1016EJ Amsterdam
Chamber of Commerce : Amsterdam
File Number : 711 617 67

Table of contents

	Page
1. Balance Sheet as at 31 st March 2021	3
2. Profit and Loss account for the year ended 31 st March 2021	4
3. Notes to the Financial Statements	5-10
4. Other Information	11

Balance Sheet as at 31st March 2021

(Before proposed result appropriation)

	<u>Notes</u>	<u>31-Mar-2021</u> EUR	<u>31-Mar-2020</u> EUR
Fixed assets			
Intangible fixed assets	1	3,284,606	3,475,942
Tangible fixed assets	2	856	1,161
Financial fixed assets	3	<u>1,024,524</u>	<u>673,808</u>
		4,309,986	4,150,911
Current assets			
Receivables, including prepayments	4	8,000	8,000
Other receivables	5	60	931
Cash and cash equivalents	6	<u>5,438</u>	<u>7,310</u>
		13,498	16,241
Short-term liabilities			
Short-term and accrued liabilities	7	<u>5,926</u>	<u>6,069</u>
Balance of current assets less short-term liabilities		7,572	10,172
Balance of assets less short-term liabilities		<u><u>4,317,558</u></u>	<u><u>4,161,082</u></u>
Shareholders' equity			
	8		
Issued and paid up capital		1,230,000	1,230,000
Share premium		3,075,000	3,075,000
Revaluation reserve		194,001	-
Retained earnings		(143,918)	(24,663)
Result for the year		(37,525)	(119,255)
		<u>4,317,558</u>	<u>4,161,082</u>
		<u><u>4,317,558</u></u>	<u><u>4,161,082</u></u>

Profit and Loss account for the year ended 31st March 2021

	<u>Notes</u>	<u>2020-21</u> EUR	<u>2019-20</u> EUR
Operating Income			
Operating Income	9	7,000.00	-
Operating expenses			
Other operating expenses	10	(9,599)	(25,628)
Depreciation and amortization	11	(191,641)	(191,642)
Total operating expenses		<u>(201,240)</u>	<u>(217,270)</u>
Result before taxation		<u>(194,240)</u>	<u>(217,270)</u>
Taxes on results		-	-
Result after taxation		<u>(194,240)</u>	<u>(217,270)</u>
Holding activities			
Results from subsidiaries	12	156,715	98,015
Net result after taxation		<u><u>(37,525)</u></u>	<u><u>(119,255)</u></u>

Notes to the Financial Statements

Activities

Poly Medicure B.V. (the "Company") is a private company with limited liability having its statutory seat in Amsterdam and its registered address at Keizersgracht 391 A, 1061EJ Amsterdam.

The Company was incorporated on 15 March 2018.

The principal business activity of the Company mainly consist of holding and financing activities.

The Company is wholly owned by Poly Medicure Limited, having its registered office at 232-B, 3rd Floor, Okhla Industrial Estate, Phase-3, New Delhi, 110020, India.

The financial year

The financial year of the Company starts on 1st April and ends on 31st March.

Principles for the valuation of assets and liabilities

The annual accounts have been prepared in accordance with accounting principles generally accepted in the Netherlands (Title 9, Book 2 of the Dutch Civil Code) and are denominated in Euro, which is the Company's functional currency.

Intangible fixed assets

Goodwill on acquisitions is capitalised and amortised on a straight-line basis over its estimated future useful life, with a maximum of 20 years.

Tangible fixed assets

Tangible fixed assets are valued at cost less accumulated depreciation and, if applicable, impairments. Depreciation is based on the useful life and calculated as a fixed percentage of the acquisition price, taking into account any residual value.

Financial fixed assets

Investments over which the Company has significant influence (considered to be over 20% of the voting shares) are valued at net assets value.

Receivables, cash and liabilities

Receivables, securities, cash at banks, cash on hands and liabilities are stated at nominal value, unless stated otherwise.

Foreign currencies

All monetary assets and liabilities denominated in foreign currencies have been converted into EUR at the rate of exchange prevailing at the balance sheet date, where as non-monetary assets denominated in foreign currencies are translated at historical rate when the transaction took place. All transactions in foreign currency made during the year under review are accounted for at the official rate of exchange prevailing on or around the date of the transaction took place. The exchange differences are reflected in the financial result.

Notes to the Financial Statements (continued...)

Impairment

As at each Balance sheet date, the Company reviewed the assets to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is determined. An assets is subject to impairment if its carrying amount exceeds its recoverable amount. Impairment losses are recognised in the profit & loss account.

Shareholders' equity

Financial instruments that are designated as equity instruments by virtue of the economic reality are presented under shareholder's equity. Payments to holders of these instruments are deducted from the shareholder's equity as a part of the profit distribution.

Equity share capital consist of ordinary shares.

Financial instruments that are designated as a financial liability by virtue of the economic reality are presented under liabilities. Interest, dividends, income and expenditure with respect to these financial instruments are recognized in the profit and loss as financial income or expense.

Consolidation exemption

The Company qualifies as a so-called "small-sized company" based on the requirements mentioned in Article 396, Title 9, Book 2 of the Netherlands Civil Code and therefore has not prepared consolidated accounts as permitted by Article 407.2, Title 9, Book 2 of the Netherlands Civil Code.

Principles for the determination of the result

Profits on transactions are recognised in the year in which they are realised, losses are taken into account as soon as they are foreseeable.

Income and expenses denominated in foreign currencies are accounted for at the official rates of exchange prevailing on the date on which the transaction took place. Translation differences due to exchange rate fluctuations between the transaction date and the settlement date or balance sheet date are recognized in the profit and loss account.

Corporate income tax

Tax on result is calculated by applying the current rate on the result for the financial year in the profit & loss account, taking into account tax losses carry-forward and tax exempt profit elements and after inclusion of non-deductible costs.

Notes to the Financial Statements (continued...)

	<u>31-Mar-2021</u>	<u>31-Mar-20</u>
	EUR	EUR
Fixed assets		
1) Intangible fixed assets		
Goodwill		
Balance at beginning	3,475,942	3,667,278
Addition during the year	-	-
Amortization	<u>(191,336)</u>	<u>(191,336)</u>
Balance at closing	<u><u>3,284,606</u></u>	<u><u>3,475,942</u></u>
Investment	3,826,725	3,826,725
Accumulated amortization	<u>(542,119)</u>	<u>(350,783)</u>
Balance at closing	<u><u>3,284,606</u></u>	<u><u>3,475,942</u></u>
2) Tangible fixed assets		
Computer & Laptop		
Balance at beginning	1,161	1,467
Addition during the year	-	-
Depreciation	<u>(305)</u>	<u>(306)</u>
Balance at closing	<u><u>856</u></u>	<u><u>1,161</u></u>
Cost	1,525	1,525
Accumulated depreciation	<u>(669)</u>	<u>(364)</u>
Balance at closing	<u><u>856</u></u>	<u><u>1,161</u></u>

On 21 January 2019, the Company purchased a laptop for business use. The cost of the laptop was Euro 1,525 which will be depreciated over the period of 5 years.

3) Financial fixed assets

3.1) Participation in subsidiaries

Plan1 Health Srl, Italy	100%	<u><u>1,024,524</u></u>	<u><u>673,808</u></u>
-------------------------	-------------	-------------------------	-----------------------

The movements in NAV in subsidiary company have been as follows:

Beginning balance	673,808	553,283
Share in result	156,715	98,015
Operational reserve	-	22,510
Revaluation reserve	<u>194,001</u>	<u>-</u>
Total NAV	<u><u>1,024,524</u></u>	<u><u>673,808</u></u>

The Company purchased 100% share capital of Plan 1 Health Srl, Italy and paid Euro 3,468,600 and Euro 761,400 on 18 June 2018 and 6 March 2019 respectively. The purchase consideration includes Goodwill of Euro 3,826,725.

Notes to the Financial Statements (continued...)

	<u>31-Mar-2021</u>	<u>31-Mar-20</u>
	EUR	EUR
Current assets		
4) Receivables, including prepayments		
Advance to supplier	200	200
Receivable from Stefano Battaglia, Mario Zearo, Fabio Venturelli	7,800	7,800
	<u>8,000</u>	<u>8,000</u>
5) Other receivables		
Prepaid rent	-	720
Deposit on rent	60	60
VAT receivable	-	151
	<u>60</u>	<u>931</u>
6) Cash and cash equivalents		
HSBC Bank - EUR	<u>5,438</u>	<u>7,310</u>
Short-term liabilities		
7) Short-term and accrued liabilities		
Trade creditors	50	921
Accrued liabilities	5,876	5,148
	<u>5,926</u>	<u>6,069</u>

Notes to the Financial Statements (continued...)

(In Euro)

8) Shareholder's equity

	Share capital	Share premium	Revaluation reserve	Retained earnings	Result for the year	Total
Balance as at 1 April 2020	1,230,000	3,075,000	-	(24,663)	(119,255)	4,161,082
Movements during the year	-	-	-	-	-	-
Allocation of result	-	-	-	(119,255)	119,255	-
Adjustment	-	-	194,001	-	-	194,001
Result for the year	-	-	-	-	(37,525)	(37,525)
Balance as at 31 March 2021	<u>1,230,000</u>	<u>3,075,000</u>	<u>194,001</u>	<u>(143,918)</u>	<u>(37,525)</u>	<u>4,317,558</u>
	Share capital	Share premium	Revaluation reserve	Retained earnings	Result for the year	Total
Balance as at 1 April 2019	1,230,000	3,075,000	-	(110)	(47,063)	4,257,827
Movements during the year	-	-	-	-	-	-
Allocation of result	-	-	-	(47,063)	47,063	-
Adjustment	-	-	-	22,510	-	22,510
Result for the year	-	-	-	-	(119,255)	(119,255)
Balance as at 31 March 2020	<u>1,230,000</u>	<u>3,075,000</u>	<u>-</u>	<u>(24,663)</u>	<u>(119,255)</u>	<u>4,161,082</u>

The share capital amounts to € 1,230,000 and consists of 1,230,000 ordinary shares with a nominal value of Eur 1 each.

Appropriation of the result

The Company's management proposes to add the result of the financial year under review to the retained earnings.

Notes to the Financial Statements (continued...)

	<u>2020-21</u> EUR	<u>2019-20</u> EUR
9) Operating Income		
Advisory Income	7,000	-
	<u>7,000</u>	<u>-</u>
10) Other operating expenses		
Bank charges	(3,003)	(3,057)
Legal fees	-	(1,116)
Professional expenses	(5,876)	(20,655)
Rent	(720)	(720)
Post & courier charges	-	(80)
	<u>(9,599)</u>	<u>(25,628)</u>
11) Depreciation and amortization		
Depreciation - Computer & Laptop	(305)	(306)
Amortization- Goodwill	(191,336)	(191,336)
	<u>(191,641)</u>	<u>(191,642)</u>
12) Results from subsidiaries		
Result participation Plan1 Health Srl, Italy	156,715	98,015
	<u>156,715</u>	<u>98,015</u>

Average number of employees

During the financial year the Company had no employee.

Directors

The Company has three directors during the financial year (Previous year : three).

Amsterdam

Sd/-
Director
Mr. Rishi Baid

Sd/-
Director
Mr. Himanshu Baid

Sd/-
Director
Mr. Alessandro Balboni

Other Information

Auditor's report

Based on article 2:396 section 6 of the Dutch Civil Code, the Company is exempt from the obligation to have the annual accounts audited by an auditor. Consequently, no audit has been requested and therefore no auditor's report is attached.

Statutory Provision on appropriation of result

Based on the Company's articles of association the result shall be at the disposal of the general meeting of shareholders. Dividend can only be distributed to the extent that the Company's shareholders' equity exceeds the reserves which must be maintained by law.

COVID-19

The COVID-19 pandemic has disrupted various business operations across the world. The company continues with its operations in a phased manner in line with directives from the authorities. The company has evaluated the impact of this pandemic on its business operations, liquidity, assets and financial position and based on management's review of current indicators and economic conditions, there is no material impact and adjustments required on its financial results as at March 31, 2021. However, the assessment of impact of COVID-19 is a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial results. The company will continue to monitor any material changes to future economic conditions and its impact, if any.

Post balance sheet date events

No events which may substantially effect the financial position of the company and which are relevant to announce in the annual accounts have occurred after the balance sheet date.